HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 388 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $2,140,058 | -85.5% | 40,872 | -88.8% | 0.00% | -87.0% |
Q1 2024 | $14,780,631 | +56.6% | 363,339 | +42.3% | 0.02% | +27.8% |
Q4 2023 | $9,436,368 | +858.2% | 255,313 | +890.3% | 0.02% | +500.0% |
Q3 2023 | $984,834 | -80.3% | 25,781 | -81.4% | 0.00% | -83.3% |
Q2 2023 | $4,990,465 | +586.2% | 138,355 | +626.5% | 0.02% | +500.0% |
Q1 2023 | $727,290 | -87.8% | 19,044 | -81.8% | 0.00% | -90.6% |
Q4 2022 | $5,958,340 | +154.0% | 104,716 | +96.4% | 0.03% | +88.2% |
Q2 2022 | $2,346,000 | +468.0% | 53,329 | +425.3% | 0.02% | +240.0% |
Q3 2021 | $413,000 | -58.2% | 10,153 | -53.3% | 0.01% | -54.5% |
Q2 2021 | $987,000 | -52.7% | 21,732 | -56.6% | 0.01% | -66.7% |
Q1 2021 | $2,087,000 | -20.5% | 50,054 | -18.6% | 0.03% | -10.8% |
Q4 2020 | $2,626,000 | +713.0% | 61,492 | +401.0% | 0.04% | +640.0% |
Q3 2020 | $323,000 | -29.6% | 12,273 | -28.3% | 0.01% | -28.6% |
Q2 2020 | $459,000 | -65.0% | 17,111 | -76.8% | 0.01% | -82.9% |
Q4 2019 | $1,310,000 | – | 73,897 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 19,816,162 | $195,784,000 | 9.33% |
BB BIOTECH AG | 5,846,564 | $57,764,000 | 2.74% |
QVT Financial LP | 4,556,090 | $45,014,000 | 2.44% |
Parametrica Management Ltd | 29,578 | $292,000 | 2.21% |
SECTORAL ASSET MANAGEMENT INC | 4,389,682 | $43,370,000 | 1.84% |
Belmont Global Advisors, Inc. | 257,000 | $2,539,000 | 1.83% |
HARVEY CAPITAL MANAGEMENT INC | 394,550 | $3,898,000 | 1.40% |
Lombard Odier Asset Management (USA) Corp | 1,350,000 | $13,338,000 | 0.70% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 6,199,685 | $61,253,000 | 0.63% |
Callan Capital, LLC | 199,230 | $1,968,000 | 0.53% |